IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

05 8 2021 07:00:02 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

13 7 2021 07:00:03 提供 Nasdaq GlobeNewswire

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

06 7 2021 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings

21 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

21 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Reveals a New Anti-LAG-3 Research Program

08 6 2021 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

04 6 2021 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

04 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

02 6 2021 07:00:02 提供 Nasdaq GlobeNewswire

Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti

01 6 2021 07:00:01 提供 Nasdaq GlobeNewswire